ProShare Advisors
NRIX icon

ProShare Advisors’s Nurix Therapeutics NRIX Stock Holding History

ProShare Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$300K Sell
19,341
-3,453
-15% -$57.3K ﹤0.01% 1342
2025
Q4 		$432K Buy
22,794
+7,180
+46% +$103K ﹤0.01% 1217
2025
Q3 		$144K Sell
15,614
-2,691
-15% -$27.9K ﹤0.01% 1778
2025
Q2 		$208K Sell
18,305
-1,401
-7% -$15.1K ﹤0.01% 1701
2025
Q1 		$234K Sell
19,706
-3,426
-15% -$57.3K ﹤0.01% 1579
2024
Q4 		$436K Buy
23,132
+7,261
+46% +$166K ﹤0.01% 1361
2024
Q3 		$357K Buy
15,871
+5,834
+58% +$132K ﹤0.01% 1346
2024
Q2 		$209K Sell
10,037
-1,941
-16% -$30.2K ﹤0.01% 1511
2024
Q1 		$176K Buy
11,978
+998
+9% +$10.7K ﹤0.01% 1703
2023
Q4 		$113K Buy
+10,980
New +$75.3K ﹤0.01% 1760
2022
Q2 		– Sell
-10,489
Closed -$148K – 2009
2022
Q1 		$148K Sell
10,489
-2,639
-20% -$46.8K ﹤0.01% 1956
2021
Q4 		$380K Sell
13,128
-377
-3% -$11.4K ﹤0.01% 1637
2021
Q3 		$405K Sell
13,505
-2,589
-16% -$79.9K ﹤0.01% 1337
2021
Q2 		$427K Buy
16,094
+4,265
+36% +$125K ﹤0.01% 1642
2021
Q1 		$368K Buy
11,829
+3,249
+38% +$123K ﹤0.01% 1671
2020
Q4 		$282K Buy
+8,580
New +$284K ﹤0.01% 1654

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

ProShare Advisors's NRIX Position: Q1 2026 in Review

ProShare Advisors reduced its Nurix Therapeutics (NRIX) stake by 15% in Q1 2026, selling an estimated $57.3K and leaving 19,341 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #1342.

ProShare Advisors first reported a position in NRIX in Q4 2020 and has held it in 16 quarters since. The position peaked at $436K in Q4 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • ProShare Advisors held 19,341 shares of Nurix Therapeutics worth $300K as of Q1 2026.
  • ProShare Advisors sold 3,453 Nurix Therapeutics shares in Q1 2026, an estimated $57.3K.
  • Nurix Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1342 holding.
  • ProShare Advisors first reported a position in Nurix Therapeutics in Q4 2020 and has held it in 16 quarters since.
  • ProShare Advisors's Nurix Therapeutics position peaked at $436K in Q4 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.